Dr Reddy's launches US speciality business

Pharmaceutical major Dr Reddy’s Laboratories (DRL) announced its US speciality business with the launch of its wholly-owned subsidiary, Promius Pharma.

Promius Pharma will initially focus on the branded dermatology market, based on a platform of strategic initiatives and internal product development activities undertaken over the last several years. Currently, its product portfolio comprises three in-licensed and co-developed dermatological products that are scheduled to launch this year.

It is developing a pipeline of topical products at the integrated product development facility in Hyderabad. Promius’ current portfolio contains topical products for the treatment of psoriasis, atopic dermatitis and seborrheic dermatitis.

“With Promius Pharma, we are committed to establishing a leading position in the US dermatology market by providing innovative solutions to patients and physicians that leverage Promius’ current portfolio and future additions,” GV Prasad, vice-chairman and chief executive officer of DRL, stated in a press release on Thursday.